About ImmunoVaccine (CVE:IMV)
Immunovaccine Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The companys DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus. The company has research collaborations with companies and research organizations, including Merck KGaA, Incyte Corporation, and Leidos Inc, as well as with Zoetis. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: CVE:IMV
- CUSIP: N/A
- Web: www.imvaccine.com
- Market Cap: C$173.67 million
- Outstanding Shares: 127,701,000
- 50 Day Moving Avg: C$1.18
- 200 Day Moving Avg: C$1.24
- 52 Week Range: C$0.65 - C$1.70
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: C$0.10 per share
- Price / Book: 13.60
- Average Volume: 99,941 shs.
- Short Ratio: 0.48
Frequently Asked Questions for ImmunoVaccine (CVE:IMV)
What is ImmunoVaccine's stock symbol?
ImmunoVaccine trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IMV."
When will ImmunoVaccine make its next earnings announcement?
Where is ImmunoVaccine's stock going? Where will ImmunoVaccine's stock price be in 2017?
0 equities research analysts have issued 1-year target prices for ImmunoVaccine's stock. Their forecasts range from C$1.70 to C$1.70. On average, they anticipate ImmunoVaccine's stock price to reach C$1.70 in the next twelve months. View Analyst Ratings for ImmunoVaccine.
Who are some of ImmunoVaccine's key competitors?
Some companies that are related to ImmunoVaccine include SIGA Technologies (SIGA), Anavex Life Sciences Corp. (AVXL), XOMA Corporation (XOMA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Concordia International Corp (CXR), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON) and Windtree Therapeutics (WINT).
How do I buy ImmunoVaccine stock?
Shares of ImmunoVaccine and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ImmunoVaccine's stock price today?
MarketBeat Community Rating for ImmunoVaccine (CVE IMV)MarketBeat's community ratings are surveys of what our community members think about ImmunoVaccine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ImmunoVaccine stock can currently be purchased for approximately C$1.36.
Consensus Ratings for ImmunoVaccine (CVE:IMV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||C$1.70|Consensus Price Target History for ImmunoVaccine (CVE:IMV)
Analysts' Ratings History for ImmunoVaccine (CVE:IMV)
(Data available from 10/22/2015 forward)
|12/16/2016||Mackie||Lower Price Target||C$1.85 -> C$1.70|
Earnings History for ImmunoVaccine (CVE:IMV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ImmunoVaccine (CVE:IMV)
Current Year EPS Consensus Estimate: $-0.08 EPS
Dividend History for ImmunoVaccine (CVE:IMV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ImmunoVaccine (CVE:IMV)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ImmunoVaccine (CVE:IMV)
Latest Headlines for ImmunoVaccine (CVE:IMV)
Loading headlines, please wait.
ImmunoVaccine (IMV) Chart for Sunday, October, 22, 2017